Airway Clearance Devices
Customize your policy alerts
Sign up for all CareSource policy alerts
Know when CareSource releases new policies or updates existing guidance.
Monitor payer policy activity
Defines medical necessity, coverage criteria, and exclusions for mechanical insufflation-exsufflation devices, high-frequency chest compression devices, and oscillation and lung expansion (OLE) devices for members, including clinical criteria and rental/purchase guidance.
Added a 2 month trial period requirement and effectiveness criteria for continued use of high-frequency chest compression devices.
Added Section III addressing Oscillation and Lung Expansion (OLE) devices and designated them as unproven for outpatient use.
Updated references and added effectiveness criteria to II.D.1.
Coverage Criteria for Airway Clearance Devices
Mechanical Insufflation-Exsufflation - Medically Necessary
Covered when ALL of the following are met:
All conditions required
High Frequency Chest Compression - Medically Necessary
Covered when ANY of the following clinical criteria is met:
Any one criterion sufficient
OLE Devices - Unproven / Not Recommended
Stance on OLE devices:
Policy states not recommended for outpatient use
Chronic bronchitis and chronic obstructive pulmonary disease (COPD) without a confirmed diagnosis of bronchiectasis do not meet the coverage criteria for high-frequency chest compression (HFCWO) devices. This exclusion is based on the policy requirement that HFCWO is medically necessary only when bronchiectasis has been confirmed by CT and meets the additional clinical characterization criteria (for example, daily productive cough for ≥ 6 continuous months or frequent exacerbations).
Combination oscillation and lung expansion (OLE) devices (for example, Volara, BiWaze, MetaNeb4) are considered of unproven efficacy and are not recommended for outpatient use due to insufficient evidence and documented safety concerns. The policy cites limited and incomplete clinical trial data and specific safety signals including two Class 1 FDA recalls and reported adverse events, and therefore treats outpatient use of these combination OLE systems as not medically necessary/unproven.
Coding and Trial Parameters
| E0482 | Mechanical insufflation-exsufflation device |
| E0483 | High frequency chest compression device (HFCWO) |
Provider Requirements, Documentation, and Billing Guidance
HFCWO 2-month trial and CMN required for continuation
High-frequency chest compression (HFCWO/E0483) devices require an initial 2-month trial; if continued use is requested after that trial in a residential setting, submit a Certificate of Medical Necessity documenting device effectiveness during the trial to support continued rental or purchase.
- CMN must attest to effectiveness during the trial (e.g., decreased infections, hospitalizations, antibiotic use).
- CMN should specify any change in duration or frequency of therapy and recommend additional rental or purchase when applicable.
Document qualifying diagnosis and clinical impairments for MIE (E0482)
Mechanical insufflation-exsufflation devices (E0482) require documentation that the member meets all listed clinical criteria: presence of neuromuscular or chest wall disease, significant impairment of chest wall/diaphragmatic movement causing inability to clear secretions, inadequate response or intolerance to chest percussion and postural drainage, and absence of bullous emphysema, pneumomediastinum, or pneumothorax.
- Examples of qualifying neuromuscular/chest wall diseases include ALS, congenital muscular dystrophies, Duchenne muscular dystrophy, multiple sclerosis, post-poliomyelitis, spinal cord injury, and spinal muscle atrophy.
- Provider must document intolerance or inadequate response to chest percussion and postural drainage.
Document inadequate response/intolerance to conventional chest percussion and postural drainage
Before considering mechanical insufflation-exsufflation or HFCWO devices medically necessary, providers must document that conventional chest physiotherapy (chest percussion and postural drainage) was tried and found inadequate or not tolerated.
- Documentation should state the nature of the inadequate response or intolerance to chest percussion and postural drainage.
- This requirement applies to both MIE devices and HFCWO devices per policy criteria.
Provide CMN attesting effectiveness after 2-month HFCWO trial
If HFCWO use continues after the initial 2-month trial in a residential setting, provide a Certificate of Medical Necessity attesting to the device’s effectiveness during the trial (including decreased infections, hospitalizations, or antibiotic use), note any changes in therapy duration/frequency, and state the recommendation for additional rental or purchase.
- CMN must include an attestation to effectiveness during the trial and every previous rental period (examples: decreased infections, hospitalizations, antibiotic use).
- CMN should specify any change in therapy duration or frequency and recommend either additional rental or purchase if applicable.
Device duplication is not medically necessary
Use of both a high frequency chest compression device (E0483) and a mechanical insufflation-exsufflation device (E0482) for the same member is not reasonable and necessary and may be denied; do not request concurrent coverage for both devices.
- If both devices are submitted for the same member, expect denial as not reasonable and necessary per policy.
MIE use for unsupported indications is non-covered
Mechanical insufflation-exsufflation devices are not covered or reimbursable for any indication not explicitly listed in the policy; do not bill or request authorization for unsupported indications.
- Providers must ensure the requested indication matches the policy’s covered list (neuromuscular or chest wall disease with the specified clinical criteria).
Background and Clinical Context
Airway secretions are normally cleared by ciliary action and coughing. Conditions such as asthma, COPD, cystic fibrosis, neuromuscular disease, or chest wall disorders can impair mucus clearance and cough effectiveness, leading to secretion retention that increases morbidity and mortality. Conventional chest physiotherapy (percussion and postural drainage) can improve clearance but may be labor-intensive or not tolerated; airway clearance devices are considered when conventional methods are inadequate or not tolerated to assist secretion mobilization and expectoration.
Device Definitions
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.